Chronic administration of dehydroepiandrosterone (DHEA) to female monkey and rat has no effect on mammary gland histology

Journal of Steroid Biochemistry and Molecular Biology

Volumn 108, Issue 1-2, 2008, Pages 102-108

  Pelletier, G ^a   Labrie, C ^a   Martel, C ^a   Labrie, F ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Androgens; DHEA; Estrogens; Histology; Intracrinology; Mammary gland

Indexed keywords

ANDROGEN; ESTRADIOL; ESTROGEN; PRASTERONE; PRASTERONE SULFATE; TESTOSTERONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ESTRADIOL BLOOD LEVEL; FEMALE; MAMMARY GLAND; MONKEY; NONHUMAN; RAT; TESTOSTERONE BLOOD LEVEL;

ADMINISTRATION, ORAL; ANIMALS; DEHYDROEPIANDROSTERONE; DRUG EVALUATION, PRECLINICAL; FEMALE; MACACA FASCICULARIS; MAMMARY GLANDS, ANIMAL; RATS; RATS, SPRAGUE-DAWLEY; STEROIDS; TIME FACTORS;

ANIMALIA; PRIMATES; RATTUS;

EID: 38649113854     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2007.07.002     Document Type: Article

References (24)

1. Labrie F., Belanger A., Simard J., Van L.-T., and Labrie C. DHEA and peripheral androgen and estrogen formation: intracrinology. Ann. NY Acad. Sci. 774 (1995) 16-28
2. Labrie F., Luu-The V., Labrie C., and Simard J. DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. Front. Neuroendocrinol. 22 (2001) 185-212
3. Labrie C., Bélanger A., and Labrie F. Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology 123 (1988) 1412-1417
4. Labrie F., Belanger A., Dupont A., Luu-The V., Simard J., and Labrie C. Science behind total androgen blockade: from gene to combination therapy. Clin. Invest. Med. 16 (1993) 475-492
5. Labrie F., Bélanger A., Bélanger P., Bérubé R., Martel C., Cusan L., Gomez J., Candas B., Chaussade V., Castiel I., Deloche C., and Leclaire J. Metabolism of DHEA in postmenopausal women following percutaneous administration. J. Steroid Biochem. Mol. Biol. 103 (2007) 178-188
6. Morales A.J., Nolan J.J., Nelson J.C., and Yen S.S.C. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J. Clin. Endocrinol. Metab. 78 (1994) 1360-1367
7. Diamond P., Cusan L., Gomez J.L., Belanger A., and Labrie F. Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. J. Endocrinol. 150 Suppl. (1996) S43-S50
8. Baulieu E.E., Thomas G., Legrain S., Lahlou N., Roger M., Debuire B., Faucounau V., Girard L., Hervy M.P., Latour F., Leaud M.C., Mokrane A., Pitti-Ferrandi H., Trivalle C., de Lacharriere O., Nouveau S., Rakoto-Arison B., Souberbielle J.C., Raison J., Le Bouc Y., Raynaud A., Girerd X., and Forette F. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEA age study to a sociobiomedical issue. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 4279-4284
9. Bonneterre J., Thurlimann B., Robertson J.F., Krzakowski M., Mauriac L., Koralewski P., Vergote I., Webster A., Steinberg M., and von Euler M. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. J. Clin. Oncol. 18 (2000) 3748-3757
10. Mouridsen H., Gershanovich M., Sun Y., Perez-Carrion R., Boni C., Monnier A., Apffelstaedt J., Smith R., Sleeboom H.P., Janicke F., Pluzanska A., Dank M., Becquart D., Bapsy P.P., Salminen E., Snyder R., Lassus M., Verbeek J.A., Staffler B., Chaudri-Ross H.A., and Dugan M. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J. Clin. Oncol. 19 (2001) 2596-2606
11. Goss P. Anti-aromatase agents in the treatment and prevention of breast cancer. Cancer Control 9 (2002) 2-8
12. Dimitrakakis C., Zhou J., Wang J., Belanger A., LaBrie F., Cheng C., Powell D., and Bondy C. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause 10 (2003) 292-298
13. Segaloff A., Gordon D., Horwitt B.N., Schlosser J.V., and Murison P.J. Hormonal therapy in cancer of the breast. 1. The effect of testosterone propionate therapy on clinical course and hormonal excretion. Cancer 4 (1951) 319-323
14. Tormey D.C., Lippman M.E., Edwards B.K., and Cassidy J.G. Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann. Intern. Med. 98 (1983) 139-144
15. Ingle J.N., Twito D.I., Schaid D.J., Cullinan S.A., Krook J.E., Mailliard J.A., Tschetter L.K., Long H.J., Gerstner J.G., Windschitl H.E., Levitt R., and Pfeifle D.M. Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer: a phase II study. Cancer 67 (1991) 886-891
16. Gordan G.S. Anabolic-androgenic steroids. Handbook of Experimental Pharmacology vol. 43 (1976), Springer-Verlag, Berlin, New York pp. 499-513
17. Li S., Yan X., Bélanger A., and Labrie F. Prevention by dehydroepiandrosterone of the development of mammary carcinoma induced by 7,12-dimethylbenz(a)anthracene (DMBA) in the rat. Breast Cancer Res. Treat. 29 (1993) 203-217
18. Sourla A., Martel C., Labrie C., and Labrie F. Almost exclusive androgenic action of dehydroepiandrosterone in the rat mammary gland. Endocrinology 139 (1998) 753-764
19. Leblanc M., Labrie C., Bélanger A., Candas B., and Labrie F. Bioavailability and pharmacokinetics of dehydroepiandrosterone in the cynomolgus monkey. J. Clin. Endocrinol. Metab. 88 9 (2003) 4293-4302
20. Labrie C., Flamand M., Bélanger A., and Labrie F. High bioavailability of DHEA administered percutaneously in the rat. J. Endocrinol. 150 (1996) S107-S118
21. Wierman M.E., Basson R., Davis S.R., Khosla S., Miller K.K., Rosner W., and Santoro N. Androgen therapy in women: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 91 (2006) 3697-3710
22. Gammon M.D., and Thompson W.D. Polycystic ovaries and the risk of breast cancer. Am. J. Epidemiol. 134 (1991) 818-824
23. Labrie F., Luu-The V., Labrie C., Belanger A., Simard J., Lin S.X., and Pelletier G. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr. Rev. 24 (2003) 152-182
24. Ulrich P. Testosterone (hormone mâle) et son role possible dans le traitement de certains cancers du sein. Acta Unio Int. Contra Cancrum (1939) 377-379